Halo Labs specializes in advanced particle analysis technologies that significantly enhance the development and manufacturing processes of biotherapeutics. Their innovative Aura family of particle analyzers employs Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) to provide high-throughput, low-volume analysis of visible and subvisible particles. This technology allows researchers to obtain critical data on particle size, morphology, and distribution with minimal sample volumes, making it particularly beneficial for protein, antibody, gene, and cell therapies. The Aura analyzers are designed to meet stringent regulatory standards, such as USP 788, ensuring compliance while delivering rapid and reliable results.

The Aura product line includes several configurations tailored to specific therapeutic workflows, such as Aura PTx for protein and antibody therapies, Aura GT for gene therapies, and Aura CL for cell therapies. Each model is engineered to facilitate quick decision-making regarding formulation, quality, and safety by providing detailed insights into particulate contamination and stability. By rethinking traditional particle analysis methods, Halo Labs enables biotherapeutic developers to streamline their processes, reduce material waste, and enhance the accuracy of their findings, ultimately accelerating the path from preclinical development to clinical manufacturing.

United States

Develop instruments and methods for quantifying stability, purity, and quality in protein therapeutics and cell and gene therapy products.

Halo Labs

Company Details